Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating ...

Expansion into new indications: NeuroPace is working towards expanding its RNS System’s use for treating idiopathic generalized epilepsy (IGE) and pediatric epilepsy. The company plans to submit ...

NeuroPace outlined its three-year strategic objectives, aiming for over 20% revenue compound annual growth rate (CAGR), expanding indications for its RNS System to include additional patient ...

FDA submission planned in second half of 2025 Announced that data demonstrating best in class efficacy results from the ongoing Post-approval Study of the RNS System in adults with drug-resistant ...

NeuroPace is known for its innovative RNS System, the first brain-responsive platform that provides personalized treatment to manage seizures in patients with drug-resistant epilepsy, potentially ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders, has been making significant strides in the epilepsy treatment market with its Responsive ...

a noncash expense NeuroPace continues to expect revenue growth to be primarily driven by increasing sales of its RNS System, supported by higher sales of DIXI Medical stereo EEG products.

Reports Q4 revenue $21.47M, consensus $21.14M. “We are pleased with the strong revenue growth reported in 2024, as we continue to implement our ...

NeuroPace's revenue was $21.5 million representing growth of 19% compared to $18 million for the fourth quarter of 2023. Revenue growth was primarily driven by increased sales of our RNS System ...

NeuroPace Inc (NASDAQ:NPCE) reported a 22% increase in total revenue for 2024, reaching $79.9 million, driven by sales of the RNS system and Dixie Medical SEEG products. The company achieved ...

Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net proceeds to repurchase 100% of KCK holdings and ...